Furthermore, in a multicentre international registry (the SGLT2-i AMI PROTECT registry) recently published by Paolisso et al. [8], the authors demonstrated that the SGLT2-i use was associated with a lower risk of CI-AKI in T2DM patients with AMI, mostly in patients without CKD. The gene discussed is SLC5A2; the disease is chronic kidney disease.